Page 275 - 2021_06-Haematologica-web

Letters to the Editor
Pre-published: March 22, 2018.
Disclosures: no conflicts of interest to disclose.
Contributions: CG, GH and YY designed the project and wrote the manuscript: CG, HC and all other authors performed the experiments and interpreted the data.
Acknowledgments: the authors would like to thank Dr. Siegfried Janz, and Fenghuang Zhan from the University of Iowa for their scien- tific support.
Funding: this work was supported by National Natural Science Foundation of China 81770220, 81600177, 81670200, 81500166 (to CG & YY); National key research and development program-pre- cision medicine sub-program 2016YFC0905900 (to YY); The 2016 outstanding youth fund of Jiangsu Province BK20160048 (to YY); Natural Science Foundation of Jiangsu Province BK20161041, 16KJB310009 (to CG); The Priority Academic Program Development of Jiangsu Higher Education Institutions for Chinese Medicine.
References
1. Bianchi G, Anderson KC. Understanding biology to tackle the dis- ease: multiple myeloma from bench to bedside, and back. CA Cancer J Clin. 2014;64(6):422-444.
2. Barlogie B, Mitchell A, van Rhee F, Epstein J, Morgan GJ, Crowley J. Curing myeloma at last: defining criteria and providing the evi- dence. Blood. 2014;124(20):3043-3051.
3. Pawlyn C, Morgan GJ. Evolutionary biology of high-risk multiple myeloma. Nat Rev Cancer. 2017;17(9):543-556.
4. Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG. Cancer drug resistance: an evolving paradigm. Nat Rev Cancer. 2013;13(10):714-726.
5. Bolli N, Biancon G, Moarii M, et al. Analysis of the genomic land- scape of multiple myeloma highlights novel prognostic markers and disease subgroups. Leukemia. 2018;32(12):2604-2616.
6. Yang Y, Shi J, Tolomelli G, et al. RARalpha2 expression confers myeloma stem cell features. Blood. 2013;122(8):1437-1447.
7.Herranz N, Gallage S, Mellone M, et al. mTOR regulates MAP- KAPK2 translation to control the senescence-associated secretory phenotype. Nat Cell Biol. 2015;17(9):1205-1217.
8. He J, Liu Z, Zheng Y, et al. p38 MAPK in myeloma cells regulates osteoclast and osteoblast activity and induces bone destruction. Cancer Res. 2012;72(24):6393-6402.
9. Li JY, Li RJ, Wang HD. gamma-secretase inhibitor DAPT sensitizes t-AUCB-induced apoptosis of human glioblastoma cells in vitro via blocking the p38 MAPK/MAPKAPK2/Hsp27 pathway. Acta Pharmacol Sin. 2014;35(6):825-831.
10. Lin SP, Lee YT, Wang JY, t al. Survival of cancer stem cells under hypoxia and serum depletion via decrease in PP2A activity and acti- vation of p38-MAPKAPK2-Hsp27. PloS One. 2012;7(11):e49605.
11. Shaughnessy JD, Jr., Zhan F, Burington BE, et al. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood. 2007;109(6):2276-2284.
12. Carrasco DR, Tonon G, Huang Y, et al. High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients. Cancer Cell. 2006;9(4):313-325.
13. Zhan F, Huang Y, Colla S, et al. The molecular classification of mul- tiple myeloma. Blood. 2006;108(6):2020-2028.
14. Mulligan G, Mitsiades C, Bryant B, et al. Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib. Blood. 2007;109(8):3177-3188.
15. Konermann S, Brigham MD, Trevino AE, et al. Genome-scale tran- scriptional activation by an engineered CRISPR-Cas9 complex. Nature. 2015;517(7536):583-588.
haematologica | 2021; 106(6)
1777